Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 9061 results

  1. Transvaginal radiofrequency ablation for symptomatic uterine fibroids

    In development Reference number: GID-HTG10538 Expected publication date: TBC

  2. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    In development Reference number: GID-TA11625 Expected publication date:  16 December 2026

  3. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

  4. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

  5. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

  6. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

  7. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

  8. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

  9. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

  10. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

  11. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

  12. Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]

    Awaiting development Reference number: GID-TA11473 Expected publication date: TBC

  13. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date: TBC

  14. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  29 July 2026

  15. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC